Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) EPS (Weighted Average and Diluted) (2019 - 2026)

Pliant Therapeutics has reported EPS (Weighted Average and Diluted) over the past 8 years, most recently at -$0.32 for Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) rose 65.22% to -$0.32 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.84 through Mar 2026, up 48.89% year-over-year, with the annual reading at -$2.43 for FY2025, 29.97% up from the prior year.
  • EPS (Weighted Average and Diluted) was -$0.32 for Q1 2026 at Pliant Therapeutics, up from -$0.38 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at -$0.32 in Q1 2026 and troughed at -$0.95 in Q3 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.71 (2025), against an average of -$0.7.
  • Year-over-year, EPS (Weighted Average and Diluted) crashed 35.71% in 2024 and then surged 65.22% in 2026.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.72 in 2022, then increased by 4.17% to -$0.69 in 2023, then decreased by 17.39% to -$0.81 in 2024, then skyrocketed by 53.09% to -$0.38 in 2025, then grew by 15.79% to -$0.32 in 2026.
  • Per Business Quant, the three most recent readings for PLRX's EPS (Weighted Average and Diluted) are -$0.32 (Q1 2026), -$0.38 (Q4 2025), and -$0.43 (Q3 2025).